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Abstract 
Introduction 
Nicotinic acetylcholine receptors (nAChRs) are of great interest because they are implicated in 
higher brain functions. Nuclear medical imaging is one of the useful techniques for noninvasive 
evaluation of physiological and pathological function in living subjects. Recent progress in nuclear 
medical imaging modalities enables the clear visualization of the organs of small rodents. Thus, 
translational research using nuclear medical imaging in transgenic mice has become possible and 
helps to elucidate human disease pathology. However, imaging of α4β2 nAChRs in the mouse brain 
has not yet been performed. The purpose of this study was to assess the feasibility of single-photon 
emission computed tomography (SPECT) with 5-[123I]iodo-3-[2(S)-azetidinylmethoxy]pyridine 
([123I]5IA) for evaluating α4β2 nAChR availability in the mouse brain. 
Methods 
A 60-min dynamic SPECT imaging session of α4β2 nAChRs in the mouse brain was performed. The 
regional distribution of radioactivity in the SPECT images was compared to the density of α4β2 
nAChRs measured in an identical mouse. Alteration of nAChR density in the brains of Tg2576 mice 
was also evaluated. 
Results 
The mouse brain was clearly visualized by [123I]5IA-SPECT and probe accumulation was 
significantly inhibited by pretreatment with (-)-nicotine. The regional distribution of radioactivity in 
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SPECT images showed a significant positive correlation with α4β2 nAChR density measured in an 
identical mouse brain. Moreover, [123I]5IA-SPECT was able to detect the up-regulation of α4β2 
nAChRs in the brains of Tg2576 transgenic mice.  
Conclusions  
[123I]5IA-SPECT imaging would be a promising tool for evaluating α4β2 nAChR availability in the 
mouse brain and may be useful in translational research focused on nAChR-related diseases. 
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1. Introduction 
Nicotinic acetylcholine receptors (nAChRs) in the human are reported to be involved in 
higher brain functions such as learning, memory, and recognition [1], and to exert anxiolytic, 
analgesic [2], and neuroprotective effects [3, 4]. Due to the variety of functions attributed to nAChRs, 
their dysfunction is related to several central nervous system disorders including Alzheimer’s disease 
(AD) [3], Parkinson’s disease [5], and schizophrenia [6]. The α4β2 subtype is one of the two 
predominant nAChR subtypes found in the human brain and mediates the majority of nAChR 
signaling [7]. Thus, elucidating how α4β2 nAChRs are associated with physiological functions and 
pathological processes is of great interest. 
Nuclear medical imaging technology is a procedure for in vivo visualization of the 
distribution of radioactive imaging probes using positron emission tomography (PET) 
and single-photon emission computed tomography (SPECT). Because this technology is noninvasive 
and highly quantitative [8], it enables to trace cellular and molecular events and quantify protein 
expression, and it is suitable for in vivo investigation of the molecular processes involved in 
physiological and pathological functions. Several imaging probes have been developed to visualize 
α4β2 nAChRs in vivo using PET and SPECT, including 
2-[18F]fluoro-3-[2(S)-azetidinylmethoxy]pyridine ([18F]2FA) [9], [18F]nifene [10], [18F]AZAN [11], 
[18F]flubatine [12], and 5-[123I]iodo-3-[2(S)-azetidinylmethoxy]pyridine ([123I]5IA) [13, 14]. 
Noninvasive imaging of nAChRs in the human brain has been successfully performed using these 
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probes. These probes have also been used to demonstrate changes in nAChR availability in the brains 
of patients with AD [15-17] and Parkinson’s disease [18], and in smokers [19].  
However, the results of clinical studies are frequently complicated and often conflicting, 
likely due to the effects of varying combinations of symptoms and environmental factors. Some 
studies have reported decreased nAChR availability in AD patients [15, 16], while others have not 
[17]. As a complementary to clinical studies, many types of transgenic mice have recently been 
developed with expression of specific altered genes that relate to human diseases. Studies using 
transgenic mice as animal models of human disease help to elucidate the functions of mutated genes 
and the pathology of the resulting disease [20]. Moreover, recent improvements to the sensitivity and 
spatial resolution of PET and SPECT allow clear visualization of the organs of small rodents. Thus, 
translational research using nuclear medical imaging in transgenic mice has become possible and can 
provide new insight into human disease pathology. However, quantitative evaluation of α4β2 nAChR 
density in the mouse brain using PET and SPECT has not yet been performed.  
The present study aimed to evaluate the feasibility of SPECT imaging of α4β2 nAChRs in 
the mouse brain. We selected SPECT because it is more commonly used than PET in clinical settings. 
We chose to use [123I]5IA as a probe because it has been previously utilized for imaging of α4β2 
nAChRs and its safety and validity in rodents, non-human primates, and humans have been 
confirmed [21, 22]. In the present study, dynamic SPECT imaging of α4β2 nAChRs in the mouse 
brain was performed and the cerebral distribution of radioactivity as determined by image analysis 
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was compared with the density of α4β2 nAChRs in an identical mouse brain. In vivo inhibition by 
(-)-nicotine pretreatment was also performed to evaluate the specificity of [123I]5IA binding. We also 
investigated whether [123I]5IA-SPECT is sensitive enough to visualize and quantify neurological 
changes that occur in the brains of a frequently used transgenic mouse model of AD that expresses 
human β-amyloid precursor protein (APP) . 
 
 
2. Materials and methods 
2.1. Animals 
Animal experiments were performed in accordance with the guidelines of the Okayama University 
Animal Care Committee. The experimental procedures were approved by the Okayama University 
Animal Care Committee. Male C57BL/6 mice (n = 29) were purchased from CLEA Japan, Inc. 
(Tokyo, Japan). Tg (APPSWE) 2576Kha transgenic mice (Tg2576), which express human APP 
containing the K670N and M671L mutations (n = 4) and age-matched wild-type littermate controls 
(n = 5) were also purchased from CLEA Japan, Inc.. All mice were kept at a constant ambient 
temperature under a 12-hour light/dark cycle with free access to food and water. 
 
2.2. Materials 
Sodium [123I]iodide and sodium [125I]iodide were purchased from FUJIFILM RI Pharma Co., 
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Ltd. (Tokyo, Japan) and MP Biomedicals, Inc. (Santa Ana, CA, USA), respectively. The stannyl 
precursor of [123/125I]5IA, 
5-trimethylstannyl-3-[1-tert-butoxycarbonyl-2(S)-azetidinylmethoxy]pyridine, was obtained from 
ABX GmbH (Radeberg, Germany). (-)-nicotine was purchased from Nacalai Tesque, Inc. (Kyoto, 
Japan). L-[N-methyl-3H]nicotine (80 Ci/mmol) was purchased from American Radiolabeled 
Chemicals Inc. (St. Louis, MO, USA). All other reagents were purchased from Wako Pure Chemical 
Industries, Ltd. (Osaka, Japan) and Nacalai Tesque, Inc.. Solutions were used without further 
purification. 
 
2.3. Radiosynthesis 
Radioiodination was performed according to a previous report [23]. Subsequent 
deprotection, extraction, and purification by high-performance liquid chromatography (HPLC) were 
performed by a previously reported method [14], except that a different column (InertSustin C18, 10 
× 250 mm, GL Sciences Inc., Tokyo, Japan) and flow rate (3 mL/min) were used. After rotary 
evaporation of the HPLC eluent, the residue was formulated in 0.9% saline. The radiochemical 
purity was checked by thin-layer chromatography (chloroform/methanol/25% ammonia solution = 
9/1/0.1, Rf = 0.47). The [123I]5IA and [125I]5IA were obtained with a radiochemical yield of 54% and 
44%, and a radiochemical purity of > 96% and > 97%, respectively. 
 
9 
 
2.4. Biodistribution in mice 
C57BL/6 mice (n = 4) received injections of [125I]5IA (150 kBq) via the tail vein. The mice 
were killed by decapitation at 5, 15, 30, and 60 min after the injection. The brains were immediately 
harvested and divided into five regions (thalamus, cerebellum, striatum, hippocampus, and cortex). 
The divided regions were weighed and their radioactivity was measured by a gamma counter 
(AccuFLEXγ, Hitach Aloka Medical, Ltd., Tokyo, Japan). The results were expressed as the 
percentage injected dose per gram tissue (%ID/g). 
 
2.5. SPECT study in C57BL/6 mice 
2.5.1. Dynamic SPECT/CT imaging 
SPECT/CT imaging was performed by using a Triumph SPECT2/CT (TriFoil Imaging., 
Chatsworth, CA, USA) with specially designed multi-pinhole collimators (75A10). The energy 
window was ± 20% and centered on the iodine-123 photopeak (159 keV) with a cadmium zinc 
telluride (CZT) detector. SPECT images were acquired in continuous rotation mode with 16 
projections per camera for 360˚ and 40 s per projection with a 35 mm radius of rotation. The 
resolution and sensitivity was 0.8-mm full width at half maximum and 99.1 count/sec/MBq, 
respectively. A 3D-ordered subset expectation maximization (3D-OSEM) algorithm was applied 
using eight subsets and five iterations in FLEX-RECON software for multi-pinhole SPECT imaging. 
Images were reconstructed in 256 × 256 × 256 matrix size with dimensions of 0.75 × 0.75 × 0.75 
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mm. CT data were acquired at a 512 × 512 matrix size image representing a 91.3 mm field-of-view 
and 0.38 mm slice thickness. The tube voltage and current were set at 75 kV and 140 μA, 
respectively. All CT imaging data were reconstructed using a filtered back-projection algorithm with 
a ramp filter. The reconstructed pixels were 0.38 × 0.38 × 0.38 mm in the x, y, and z dimensions. 
[123I]5IA (8.2–12.3 MBq) was injected into each C57BL/6 mouse (n = 5) via the tail vein 
under awake conditions and the mice were anesthetized with 3% isoflurane in an anesthetic box 
immediately after injection. Each mouse was placed in a mouse imaging chamber and a 4-min CT 
scan was performed approximately 5 min after the injection. SPECT data were acquired 
approximately 10 min after injection by 4 sets of 10-min scans. Since it took 2 min for the CZT 
detectors to return to their original position after the scan finished, the total operating time of each 
scan set was 12 min. The mouse was maintained at 1.5% isoflurane anesthesia throughout the scans. 
After the SPECT/CT scans, the mice were returned to their cages and kept for 7 days to attenuate the 
radioactivity of 123I sufficiently. Then, the mice was used for the autoradiographic studies. 
 
2.5.2. Magnetic resonance imaging  
Each mouse was subjected to magnetic resonance (MR) brain imaging on the day prior to 
the SPECT study. The MRI scans were performed using a 4.7 Tesla BioSpec (Bruker BioSpin, 
Ettlingen, Germany). Three-dimensional T2-weighted images were acquired using a fast spin echo 
sequence. The following parameters were used: repetition time = 2000 ms, echo time = 65 ms, 
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number of averages = 2, flip angle = 90˚, field-of-view = 18 × 15 × 10 mm, resolution = 125 μm, and 
slice thickness = 1.0 mm. The mice were maintained at 1.5% isoflurane anesthesia throughout the 
scans. 
 
2.5.3. Image analysis 
The level of radioactivity accumulation within each brain region was determined by a 
region-of-interest (ROI) method using PMOD software ver. 3 (PMOD Technologies Ltd., Zurich, 
Switzerland). For ROI definition, the MR image was coregistered to each CT image using an 
automatic rigid matching tool with manual adjustment when needed. Two spheroidal ROIs in each 
region were symmetrically placed on the MR images, saved with a transformation matrix, and then 
applied to SPECT images in the following brain regions: thalamus (1.6 mm in diameter), cerebellum 
(1.6 mm in diameter), striatum (1.6 mm in diameter), cerebral cortex (1.6 mm in diameter), and 
hippocampus (1.0 mm in diameter). The mean radioactivity for each ROI was given as the midpoint 
of each of the 16-projection sequences. The mean radioactivity (count/voxel) was then converted to 
kBq/cc using a calibration factor of 0.014 for the 40-s-per-projection scan. These factors were 
determined by phantom scans of a 2 mL plastic tube filled with the same 123I solution used in the 
acquisition and reconstruction of data and according to the same protocol as the mouse imaging 
study. Standardized uptake values (SUVs) were calculated according to the following equation: SUV 
= radioactivity for each ROI (kBq/cc) / (injected dose [kBq] / body weight [g])×100. 
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2.6. Autoradiographic analysis of nAChR density in the mouse brain 
Animals were killed 7 days after dynamic SPECT/CT imaging, and the brains were rapidly 
removed and frozen in a mixture of dry-ice and hexane (-75°C) until sectioning. 
Ten-micrometer-thick sections were cut on a Microm HM 505 E cryostat (GMI, Inc., Ramsey, MN, 
USA) and mounted on glass slides. The slides were dried at room temperature overnight and then 
stored at -80°C until use. 
The binding of [3H]nicotine was measured using a modification of the procedure of Pauly et 
al. [24]. After preincbation in 20 mM Krebs-Ringer HEPES buffer (pH 7.4) for 30 min at 4°C, the 
sections were incubated with 4 nM [3H]nicotine in Krebs-Ringer HEPES buffer for 90 min at 4°C. 
Non-specific binding was measured in adjacent serial sections by incubation with 100 μM 
(-)-nicotine. Next, the sections were washed with Krebs-Ringer HEPES buffer for 3 min (3 × 1 min) 
at 4°C. The sections were rapidly air-dried, and then exposed to a tritium-sensitive imaging plate 
(Fuji Imaging Plate BAS-TR; Fuji Photo Film, Tokyo, Japan) along with a tritium standard (ART 
0123; American Radiolabeled Chemicals Inc.) for 20 h. 
The imaging plate was scanned using an FLX-7000 scanner (Fuji Photo Film), and the 
resulting autoradiograms were quantitatively analyzed using Multi Gauge ver. 3 software (Fuji Photo 
Film). Two independent measurements were taken from the thalamus, cerebellum, striatum, cerebral 
cortex, and hippocampus of five mice, identified using a mouse brain atlas [25]. [3H]nicotine binding 
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(fmol/mg wet weight) was calculated for each measurement after calculating the radioactive intensity 
(nCi/mg) using a standard curve obtained from images of the tritium standard. To determine the 
specific binding, non-specific binding in adjacent serial sections was subtracted from the total 
binding in each region. 
 
2.7. Nicotine treatment study 
SPECT/CT imaging were performed twice in C57BL/6 mice (n = 4). In the baseline study, 
[123I]5IA (9.3–12.6 MBq) was injected into the tail vein after subcutaneous injection of saline (100 
μL). The inhibition study was performed 7 days after the baseline study when the radioactivity had 
sufficiently attenuated. In the inhibition study, (-)-nicotine (10 mg/kg) was subcutaneously injected, 
and 5 min later [123I]5IA (9.2–11.2 MBq) was injected into the tail vein. In both studies, a single set 
of 30-min SPECT scans of brain was performed 45 min after the injection of [123I]5IA, followed by a 
5-min CT scan. The mice were maintained at 1.5% isoflurane anesthesia throughout the scans. 
SPECT images were acquired using 16 projections per camera for 360˚ and 120 s per projection. The 
obtained mean radioactivity (count/voxel) was converted to kBq/cc using a calibration factor 0.039 
for the 120-s-per-projection scan. MR imaging and image analysis were performed in the same way 
as described in the section 2.5. 
 
2.8. SPECT study in Tg2576 mice 
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A 60-min dynamic SPECT imaging was performed in Tg2576 mice and littermate wild-type 
mice (13 months of age, n = 4–5 per group, [123I]5IA dose; 8.1–12.9 MBq). MR imaging and image 
analysis were performed in the same way as described in the section 2.5. After completion of scans, 
the mice were returned to their cages and kept for 7 days to allow attenuation of radioactivity. Seven 
days after SPECT/CT imaging, each mouse was killed and the binding of [3H]nicotine was measured 
using the same protocol as in the section 2.6. 
 
2.9. Statistical analysis 
GraphPad Prism ver. 5 (GraphPad, San Diego, CA, USA) was used for all statistical 
analyses. Correlation coefficients were assessed using Pearson’s analysis. Paired t-tests were used to 
compare data between the baseline and (-)-nicotine-treated SPECT studies. The other comparisons 
between two groups were performed with student’s t-test. A P value < 0.05 was considered to be 
statistically significant. All data are expressed as mean ± standard deviation (SD). 
 
 
3. Results 
3.1. Dynamic SPECT imaging and biodistribution after injection of [123/125I]5IA  
Fig. 1a shows representative coronal MR images and SPECT/CT images of mouse brain 
obtained 18, 33, 48, and 62 min after injection of [123I]5IA. The upper images show slices at the level 
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of the thalamus, which is a nAChR-rich region. The lower images show images at the level of the 
cerebellum which is a nAChR-poor region. The radioactive signal was distributed across nearly the 
whole brain in both slices 18 min after injection. At the cerebellar level, the radioactive signal was 
rapidly cleared in a time-dependent manner. In contrast, the signal at the thalamic level lasted until 
62 min after injection of [123I]5IA. The time-activity curves of the five brain regions were generated 
using ROI analyses and are shown in Fig. 1b. The times at which each SUV is given in Fig. 1b are 16, 
31, 45, and 60 min, expressed as the average of the imaging midpoints of 5 mice. Radioactive signal 
was highest in the thalamus, followed by the striatum, hippocampus, cortex, and cerebellum. With 
the exception for the thalamus, each region showed a peak signal 16 min after injection, followed by 
gradual clearance. In the thalamus, [123I]5IA signal increased until 31 min after injection and then 
gradually decreased. In the biodistribution study, the radioactive signal was highest in the thalamus, 
with slightly lower levels in the striatum, hippocampus, and cerebral cortex, and the lowest levels in 
the cerebellum (Fig. 1c). These orders were in accordance with the SPECT study. 
 
3.2. Comparison of in vivo SPECT analysis with autoradiographic analysis of nAChR density 
determined in an identical mouse brain 
The density of α4β2 nAChRs in each brain region as determined by [3H]nicotine 
autoradiography was in accordance with a previous report [24]. In our preliminary biodistribution 
analysis, the brain-to-blood ratio increased in a time-dependent manner and the highest value was 
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obtained 60 min after [125I]5IA injection among the time points examined (5–60 min). Therefore, we 
compared SUVs 60 min after injection with the density of α4β2 nAChRs indicated by [3H]nicotine 
binding. The in vivo SPECT signal accumulation as determined by the ROI method showed a 
significant positive correlation with [3H]nicotine binding measured in an identical mouse brain (Fig. 
2a, R = 0.55, P < 0.005 at 60 min). Moreover, the binding potential ratios (BPR = radioactivity in a 
target region / radioactivity in the cerebellum) [26] calculated using the data obtained 60 min after 
the [123I]5IA injection showed a positive correlation with α4β2 nAChR density (Fig. 2b, R = 0.45, P 
< 0.01 at 60 min). 
 
3.3. Effect of nicotine pretreatment on [123I]5IA SPECT images  
Fig. 3a shows thalamic SPECT/CT images of baseline and nicotine treatment studies 
obtained 60 min after injection of [123I]5IA. Compared to baseline conditions (Fig. 3a, left image), 
radioactivity accumulation was significantly decreased by pretreatment with (-)-nicotine (Fig. 3a, 
right image). As shown in Fig. 3b, pretreatment with (-)-nicotine reduced radioactivity 
accumulation by 43%, 31%, 27%, and 23% in the thalamus, striatum, hippocampus, and cortex, 
respectively. In contrast, nicotine pretreatment did not result in significant signal reduction in the 
cerebellum. 
 
3.4. Changes in [123I]5IA binding and nAChR density in mouse model of Alzheimer’s disease 
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[123I]5IA-SPECT of brains of Tg2576 mice showed higher signal accumulation compared to 
wild-type littermate controls (Fig. 4a). This finding is consistent with the increase in [3H]nicotine 
binding in the brains of Tg2576 mice (Fig. 4b). In particular, [123I]5IA accumulation in the thalamus 
was significantly increased compared to wild-type mice (22%, P < 0.05). Similarly, [3H]nicotine 
binding in the thalamus showed a significant increase in Tg2576 compared to wild-type mice (28%, 
P < 0.05 ). These results suggest that nAChRs are up-regulated in the Tg2576 mouse brain. 
 
 
4. Discussion 
The present study provides the first evaluation of SPECT imaging of α4β2 nAChRs in the 
mouse brain. The living mouse brain was clearly visualized and levels of radioactivity accumulation 
in each brain region, as determined by ROI analysis, showed a significant positive correlation with 
α4β2 nAChR density determined in an identical mouse brain. Pretreatment with (-)-nicotine 
significantly inhibited the accumulation of [123I]5IA in the brain. These results indicate that the 
[123I]5IA-SPECT signal was specific to α4β2 nAChRs, and that [123I]5IA-SPECT signal intensity can 
be used as an indicator of α4β2 nAChR density. The extent of the decrease in radioactivity after 
nicotine treatment was lower than in a previous study [23], and could be attributable to an effect of 
anesthesia. It was reported that higher radioactivity was accumulated in the brain under isoflurane 
anesthesia compared with the conscious condition [27]. Therefore, slow clearance of [123I]5IA from 
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the brain under isoflurane anesthesia could cause the low baseline/blocking ratios compared to the 
previous study that was performed in the conscious condition. Furthermore, up-regulation of α4β2 
nAChRs in Tg2576 mice could be detected by SPECT/CT imaging with [123I]5IA. Therefore, 
[123I]5IA-SPECT will be a useful tool for in vivo investigation of altered α4β2 nAChR expression in 
transgenic mice with genes modifications related to human diseases. 
Due to the small size of the mouse brain and the close proximity between regions, precise 
placement of ROIs is important. For this purpose, co-registration of MR and SPECT/CT images was 
performed using the skulls and orbits as references. ROIs were placed on MR images, and then 
applied to SPECT images. To avoid underestimation of radioactive signal due to partial volume 
effects, the radius of the spheroidal ROIs was varied to fit the anatomical size of each region. Despite 
these precautions, the radioactivity in a region may be overestimated if high radioactivity 
accumulates in an adjacent regions, such as in the case of the Harderian gland [28]. In this study, the 
hippocampus and striatum’s anatomically close position to the thalamus, which showed significant 
radioactivity accumulation, is concerned. Although radioactivity accumulation as determined by the 
dissection method in the cortex, striatum, and hippocampus were nearly the same level, SUVs in the 
striatum and hippocampus were higher than those in the cortex, suggesting an effect of radioactivity 
in the thalamus on these neighboring regions. However, it should be noted that a significant positive 
correlation was observed between SPECT signal intensity and nAChR density regardless of whether 
the striatum and hippocampus were included (Fig. 2a) or excluded (R = 0.75, P < 0.005 at 60 min, 
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data not shown).  
In the present study, we used [3H]nicotine as a radioligand to determine α4β2 nAChR 
density in the mouse brain. Although [3H]nicotine has an affinity not only to α4β2 nAChRs, but also 
to α3β2 and α3β4 nAChRs [29], in rodent brains, more than 72% of nAChRs were found to be of the 
α4β2 subtype in the 4 regions evaluated in this study, except in the cerebellum [30]. Therefore, 
[3H]nicotine binding would be mainly attributable to α4β2 nAChRs and could be used as an index of 
α4β2 nAChR density, at least in the cortex, striatum, hippocampus, and thalamus. In the cerebellum, 
since 51% of nAChRs was of the α4β2 subtype and 49% was of the α3β4 subtype, α4β2 nAChR 
density might be overestimated if judged from the [3H]nicotine binding. However, the effect of 
overestimation would be limited because the cerebellum is a nAChR-poor region (only one-fifth to 
one-third of [125I]5IA binding compared with the other 4 regions). 
A limitation of the present study is the lack of kinetic analyses of the SPECT imaging data. 
In human and non-human primates, tracer kinetic analyses using imaging and blood sampling 
techniques have been performed to calculate distribution volume or binding potential of tracers [22, 
31]. However, in the case of mice, it is difficult to collect arterial blood constantly throughout a 
PET/SPECT scan because of their small blood volume. It is possible to calculate receptor density 
without blood sampling if a reference region in the brain is used that lacks expression of an imaging 
target. For example, Okada et al., used the corpus callosum as a reference region to calculate the 
binding potential of [18F]2FA , revealing low availability of nAChRs in patients with AD [32]. 
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However, this method cannot be applied in small animal SPECT imaging because the spatial 
resolution of SPECT is not high enough to distinguish the corpus callosum from other regions. 
Pretreatment with (-)-nicotine did not affect [123I]5IA accumulation in the cerebellum, suggesting that 
the cerebellum may be used as a reference region when using this probe in the mouse brain. In our 
SPECT study, BPR calculated using the data obtained 60 min after the [123I]5IA injection showed a 
positive correlation with α4β2 nAChR density (Fig. 2b). Other researchers have calculated the BPR 
using the cerebellum as a reference region in the rat brain [33]. Therefore, semi-quantitative analysis 
of nAChR density may be possible using PET/SPECT imaging in rodent brains, though further 
validation will be necessary. 
SPECT is more widely available than PET in clinical settings. This is a significant 
advantage for the use of nuclear medical imaging in translational research. Although SPECT is less 
quantitative than PET, techniques have recently been developed to increase its quantitative capacity, 
such as algorithms to improve the quality of reconstructed images [34] and methods for the precise 
correction of attenuation and scattering effects [35, 36]. In addition to these techniques, improvement 
in the sensitivity and spatial resolution of SPECT will increase its quantitative capability in the 
future.  
Tg2576 transgenic mice expressing the human APP with K670N and M671L mutations 
show early phenotypic changes which may reflect AD pathology such as elevation of Aβ1-40/1-42 levels, 
presence of amyloid plaques, and memory and learning defects [37]. A previous autoradiography 
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study showed a significant increase in accumulations of [3H]cytisine in the thalamus of 11-month-old 
Tg2576 mice [38]. We examined whether [123I]5IA-SPECT is adequately sensitive to detect nAChR 
up-regulation in the brain of Tg2576 mice. We found a significant increase in accumulation of 
[123I]5IA in the thalamus of 13-month-old Tg2576 mice compared to wild-type littermate controls. 
Therefore, we conclude that [123I]5IA-SPECT is sufficiently sensitive to assess changes in nAChRs 
in the brain of a mouse model of AD. In contrast to our findings, several studies have reported a 
decrease in nAChR availability in AD patients [15, 16]. The reason for this discrepancy in α4β2 
nAChR expression between Tg2576 mice and AD patients is unclear. It is possible that the 
phenotype of Tg2576 mice represents a pre-AD state. This hypothesis is supported by observation of 
resting-state cerebral hypermetabolism in Tg2576 mice [39] and early-onset AD patients [40], but 
not in patients with advanced AD [41]. Furthermore, no significant differences were found between 
Tg2576 and wild-type mice at 12-13 months of age in novel object recognition memory (data not 
shown) or plaque deposition [42]. Therefore, up-regulation of α4β2 nAChRs may play a role in 
mechanisms underlying neurodegeneration in early-stage AD patients with increased Aβ expression. 
Overall, these results will motivate further studies that focus on nAChR availability in transgenic 
mouse model of nAChR-related human disease. In vivo [123I]5IA-SPECT in mouse models may help 
to elucidate the mechanisms underlying changes in nAChR expression as the disease advances or to 
perform image-based screening of nAChR-targeting drugs. 
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5. Conclusion 
The mouse brain was clearly visualized using [123I]5IA-SPECT. Probe accumulation was 
significantly inhibited by pretreatment with (-)-nicotine. The regional distribution of radioactivity in 
SPECT images showed significant positive correlation with α4β2 nAChR density determined in an 
identical mouse brain. Moreover, [123I]5IA-SPECT could detect up-regulation of α4β2 nAChRs in 
the brain of Tg2576 mice. Thus, the present study indicates that [123I]5IA-SPECT provides an 
accurate assessment of α4β2 nAChR density in the mouse brain. To our knowledge, this is the first 
report to demonstrate that [123I]5IA-SPECT is a suitable tool for noninvasive measurement of α4β2 
nAChR availability in the mouse brain. This technique may be useful for translational research of 
nAChR-related diseases and image-based screening of nAChR-targeting drugs.  
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signal in the indicated brain regions. Each point represents the mean ± SD for 5 mice. (c) Cerebral 
regional uptakes of [125I]5IA (%ID/g) after intravenous administration as determined by the 
dissection method. Each point represents the mean ± SD for 4 mice. 
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1.5% isoflurane anesthesia throughout the scans.  (b) Effects of pretreatment with (-)-nicotine (10 
mg/kg) on binding of [123I]5IA in each brain region (n=4, individual identification number # 1 - 4). 
Y-axes indicate SUVs in the baseline and (-)-nicotine treatment studies in each brain region. 
Pretreatment with (-)-nicotine significantly reduced radioactivity accumulation in the thalamus (P < 
0.05 vs. baseline study).  
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